home / stock / wint / wint quote
Last: | $0.597 |
---|---|
Change Percent: | 3.63% |
Open: | $0.5782 |
Close: | $0.597 |
High: | $0.6137 |
Low: | $0.5377 |
Volume: | 1,268,481 |
Last Trade Date Time: | 06/17/2025 03:40:43 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.597 | $0.5782 | $0.597 | $0.6137 | $0.5377 | 1,268,481 | 06-17-2025 |
$0.6 | $0.5833 | $0.6 | $0.635 | $0.5416 | 2,299,770 | 06-16-2025 |
$0.592 | $0.58 | $0.592 | $0.628 | $0.5555 | 1,048,181 | 06-13-2025 |
$0.604 | $0.6485 | $0.604 | $0.6498 | $0.6 | 1,703,586 | 06-12-2025 |
$0.6998 | $0.785 | $0.6998 | $0.785 | $0.6629 | 7,916,014 | 06-11-2025 |
$0.7999 | $0.85 | $0.7999 | $1.04 | $0.733 | 109,947,294 | 06-10-2025 |
$0.5571 | $0.57 | $0.5571 | $0.57 | $0.5213 | 243,315 | 06-09-2025 |
$0.5681 | $0.6014 | $0.5681 | $0.6096 | $0.5513 | 242,797 | 06-06-2025 |
$0.587 | $0.6591 | $0.587 | $0.675 | $0.576 | 448,597 | 06-05-2025 |
$0.6652 | $0.715 | $0.6652 | $0.7246 | $0.641 | 611,618 | 06-04-2025 |
$0.79 | $0.78 | $0.79 | $0.8054 | $0.777 | 1,637,163 | 06-03-2025 |
$0.7498 | $0.71 | $0.7498 | $0.7679 | $0.6732 | 323,289 | 06-02-2025 |
$0.761 | $0.77 | $0.761 | $0.79999 | $0.7502 | 125,427 | 05-30-2025 |
$0.79 | $0.835 | $0.79 | $0.835 | $0.78 | 111,510 | 05-29-2025 |
$0.8399 | $0.8102 | $0.8399 | $0.8459 | $0.7861 | 167,609 | 05-28-2025 |
$0.799 | $0.78 | $0.799 | $0.8199 | $0.752 | 88,245 | 05-27-2025 |
$0.779 | $0.75 | $0.779 | $0.78 | $0.74 | 67,046 | 05-23-2025 |
$0.7481 | $0.7686 | $0.7481 | $0.7791 | $0.733 | 220,970 | 05-22-2025 |
$0.7875 | $0.833 | $0.7875 | $0.833 | $0.77 | 87,023 | 05-21-2025 |
$0.82 | $0.7731 | $0.82 | $0.82 | $0.749 | 159,364 | 05-20-2025 |
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. Company Name:
WINT Stock Symbol:
NASDAQ Market:
3.63% G/L:
$0.597 Last:
1,268,481 Volume:
$0.5782 Open:
$0.597 Close:
Windtree Therapeutics Inc. Website:
The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other benefits including no increase in hea...
Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting with initiation of Phase 1 High single digit royalties that could total up to $1.5 billion over the life of the drug WARRINGTO...
2025-06-10 11:58:00 ET Diversification is crucial in both life and business, encapsulated by the saying, "Don't put all your eggs in one basket." A former biotech company has embraced this principle, recently shifting its business model to acquire diverse companies. Today, it announced a pi...